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ABSTRACT Traditional culture techniques have shown that increased bacterial col-
onization is associated with viral colonization; however, the inﬂuence of viral coloni-
zation on the whole microbiota composition is less clear. We thus aimed to under-
stand the interaction of viral infections and the nasal microbiota in early life to
appraise their roles in disease development. Thirty-two healthy, unselected infants
were included in this prospective longitudinal cohort study within the ﬁrst year of
life. Biweekly nasal swabs (n  559) were taken, and the microbiota was analyzed by
16S rRNA pyrosequencing, and 10 different viruses and 2 atypical bacteria were
characterized by real-time PCR (combination of seven duplex samples). In contrast to
asymptomatic human rhinovirus (HRV) colonization, symptomatic HRV infections
were associated with lower alpha diversity (Shannon diversity index [SDI]), higher
bacterial density (PCR concentration), and a difference in beta diversities (Jaccard
and Bray-Curtis index) of the microbiota. In addition, infants with more frequent HRV
infections had a lower SDI at the end of the study period. Overall, changes in the
microbiota associated with symptomatic HRV infections were characterized by a loss
of microbial diversity. The interaction between HRV infections and the nasal microbi-
ota in early life might be of importance for later disease development and indicate a
potential approach for future interventions.
IMPORTANCE Respiratory viral infections are very frequent in infancy and of impor-
tance in acute and chronic disease development. Infections with human rhinovirus
(HRV) are, e.g., associated with the later development of asthma. We found that only
symptomatic HRV infections were associated with acute changes in the nasal micro-
biota, mainly characterized by a loss of microbial diversity. Infants with more fre-
quent symptomatic HRV infections had a lower bacterial diversity at the end of the
ﬁrst year of life. Whether the interaction between viruses and the microbiota is one
pathway contributing to asthma development will be assessed in the follow-ups of
these children. Independent of that, measurements of microbial diversity might rep-
resent a potential marker for risk of later lung disease or monitoring of early life in-
terventions.
KEYWORDS: bacteriology, human rhinovirus, microbiota, pediatric infectious disease,
respiratory viruses
Recent evidence implies that the respiratory microbiota in early life plays an impor-tant role in shaping the immune system as well as in chronic respiratory diseases
(1–6). A disordered microbiota has been reported, for example, in asthma and cystic
Received 14 October 2016 Accepted 29
October 2016 Published 23 November 2016
Citation Korten I, Mika M, Klenja S, Kieninger E,
Mack I, Barbani MT, Gorgievski M, Frey U, Hilty
M, Latzin P. 2016. Interactions of respiratory
viruses and the nasal microbiota during the
ﬁrst year of life in healthy infants. mSphere 1(6):
e00312-16. doi:10.1128/mSphere.00312-16.
Editor Rebecca Ellis Dutch, University of
Kentucky College of Medicine
Copyright © 2016 Korten et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to Philipp Latzin,
philipp.latzin@insel.ch.
M.H. and P.L. contributed equally to this article.
RESEARCH ARTICLE
Host-Microbe Biology
crossmark
Volume 1 Issue 6 e00312-16 msphere.asm.org 1
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
91
18
7 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
ﬁbrosis (CF) (7, 8); the role of the microbiota in disease development is, however, less
clear (9). A recent study has shown that in healthy infants, age and season play an
important role (10), but little is known about associations with or factors inﬂuencing the
respiratory microbiota in early life.
An important and established factor for the later onset of asthma is the occurrence
of respiratory viral infections, above all human rhinovirus (HRV) and respiratory syncy-
tial virus (RSV) (11). Furthermore, respiratory viral infections play an important role in
morbidity and early immune development during the ﬁrst year of life in otherwise
healthy infants (12–16). Despite recent data on the association between viral infections
and changes in the microbiota in adults, data for young children are scarce (17–22). Due
to several risk factors triggering both viral and bacterial infections, it is difﬁcult to draw
causal associations between those early infections and later disease development.
However, based on the long-term importance of effects early in life, the exact interac-
tion of viral colonization and microbiota in infancy seems to be of great interest.
The aim of our study was thus to assess a possible association between viral
colonization and the nasal microbiota in unselected, healthy infants within the ﬁrst year
of life. We hypothesized that the presence of a virus will change the composition of the
microbiota.
RESULTS
Study population. Thirty-two healthy, unselected term-born infants completed the
study period of 1 year, with a weekly telephone interview to assess respiratory health
and biweekly nasal swab sampling by parents. After exclusion of low-quality results for
either virus or microbiota, a total of 559 nasal swabs were evaluated both for bacterial
and virological analyses (see Fig. S1 in the supplemental material). This corresponds to
a mean of 17.5 swabs (range, 11 to 24; standard deviation [SD], 3.3) per infant. For
demographics and other risk factors, see Fig. 1 and Table 1 and see Table S1 in the
supplemental material.
FIG 1 Study design. *, weekly telephone calls with standardized interviews regarding symptoms of lower and
upper respiratory infections, wheeze, and/or cough; , biweekly analysis of nasal swab samples, including
analysis of the respiratory microbiota by PCR amplification of bacterial 16S rRNA and virological examination
with multiplex PCR. 16S rRNA pyro seq., bacterial 16S rRNA pyrosequencing. Detailed explanation of analysis
of viral colonization and the microbiota can be found in the Results section. Analysis I examined association
of viral colonization and the microbiota in the same sample. Microbiota is used as the outcome parameter.
Analysis II examined association of viral colonization and the microbiota within 3 weeks after viral colonization.
Microbiota is used as the outcome parameter, and only samples free of virus after viral colonization are
included for evaluation. Analysis III examined association of viral colonization and the microbiota within
3 weeks before viral colonization. Virus is used as the outcome parameter, and only samples free of virus
before viral colonization are included for evaluation.
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Description of microbiota and virus detection. The composition of the micro-
biota in the ﬁrst year of life was described in detail before (10). Brieﬂy, bacterial density
increased and diversity decreased within the ﬁrst year of life. If investigating the
bacterial families, the relative abundance of Staphylococcaceae and Corynebacteriaceae
was highest in the ﬁrst 3 months of life. A virus was detected in 241 samples (43%); of
those, 123 (51%) were accompanied by respiratory symptoms and 11 (5%) samples
were taken during periods with more severe respiratory symptoms (lower respiratory
tract infection [LRTI]). The most frequent virus was HRV (147 samples [26%]); all of the
other viruses analyzed were detected in 39 (7%) samples or less; RSV was found only
in 11 samples (2%) (for complete viral colonization, see Table 2). We thus grouped all
other viruses as “viruses other than HRV.” After excluding the samples cocolonized with
HRV, in 94 (17%) samples, “viruses other than HRV” were detected. Of those, 38 (40%)
were accompanied by respiratory symptoms, and 56 (60%) were not. A total of 120
samples (21%) showed HRV colonization without cocolonization with other viruses. Of
those, 69 (57.5%) were accompanied by respiratory symptoms, while 51 (42.5%) were
not. A total of 318 samples (57%) remained free of any viral colonization; of those, 77
samples (24%) did show respiratory symptoms, and 6 (2%) were taken during LRTI.
TABLE 1 Characteristics of the study populationa
Characteristic Result
Anthropometrics
Sex (female), no. (%) 13 (41)
Gestational age at birth (wk), mean (SD) 39.8 (1.2)
Length at birth (cm), mean (SD) 49.7 (2.1)
Birth wt (kg), mean (SD) 3.4 (0.5)
Season of birth, no. (%)b
Winter 8 (25)
Spring 7 (22)
Summer 9 (28)
Fall 8 (25)
Measurements
No. of wk with nasal swabs, mean (range) 17.5 (11–24)
an  32 infants.
bSeason of birth is categorized with the calendar deﬁnition of season: winter, 22 December to 20 March;
spring, 21 March to 20 June; summer, 21 June to 22 September; fall, 23 September to 21 December.
TABLE 2 Number and percentage of samples tested positive for the different viruses and
atypical bacteria
Sample typea
Samples with virus
Positive samples
accompanied by
symptoms
n % n %
Any virus 241 42 123 22
1 virus 36 6 22 4
HRV/EV 147 26 69 12
HCoV 39 7 7 1
ADV 31 5 6 1
PIV 23 4 7 1
hBoV 12 2 3 1
RSV 11 2 3 1
hPEV 8 1 2 1
hMPV 5 1 2 1
M. pneumoniae 4 1 1 0.5
Inﬂuenza A virus 1 0.5 1 0.5
Inﬂuenza B virus 1 0.5 0 0
C. pneumoniae 0 0 0 0
aTotal number of nasal swabs, n  559. Coinfections are not considered in samples when symptoms were
present. ADV, adenovirus; hBoV, human Bocavirus; HCoV, human coronavirus; hMPV, human
metapneumovirus; hPEV, human parechovirus; HRV/EV, rhinovirus/enterovirus; PIV, parainﬂuenzavirus.
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Changes in the microbiota during viral colonization. Changes in the micro-
biota during viral colonization are depicted in analysis I in Fig. 1. HRV colonization was
associated with a higher bacterial density and a lower alpha diversity: mean PCR
concentration (PCRconcn), 44 (standard deviation [SD], 35) ng/l versus 29 [SD, 29]
ng/l; Shannon diversity index (SDI), 0.9 (SD, 0.7) versus 1.3 (SD, 0.9) (Table 3).
This change occurred only during periods of symptomatic HRV infections, whereas
no change in density or diversity was found during asymptomatic HRV colonization
(Table 3). In addition, using two different approaches (Jaccard and Bray-Curtis dissim-
ilarities), there was a signiﬁcantly different bacterial composition during symptomatic
HRV infection (Jaccard, P  0.04; Bray-Curtis, P  0.034), but not during asymptomatic
HRV colonization (Jaccard, P  0.06; Bray-Curtis, P  0.1) as revealed by a nonmetric
multidimensional scaling (nMDS) ordination plot (Fig. 2).
To investigate if results were similar if only when including samples accompanied by
more severe symptoms (cough and/or wheeze), we compared samples during HRV and
upper respiratory tract infection (URTI) (n  33), HRV colonization free of symptoms
(n  51), and samples free of virus and symptoms (n  241) in a univariable model.
Results were signiﬁcant for bacterial density (PCRconcn, incidence rate ratio [IRR], 1.53;
95% conﬁdence interval [CI], 1.17 to 2.01; P  0.002) and diversity (SDI coefﬁcient [SDI
coeff], 0.15; 95% CI, 0.30 to 0.00; P  0.051), indicating comparable effects for mild
and severe infections. To maintain higher statistical power, we combined both groups
in our analysis.
Investigation on the bacterial family level showed that the relative abundance of the
different bacterial families did not change during HRV colonization, but the abundance
of “others” was signiﬁcantly decreased (25% [SD, 36%] versus 31% [SD, 32%]) (Table 3;
see Fig. S2 in the supplemental material).
TABLE 3 Unadjusted and adjusted analysis of the association of HRV colonization with the microbiota in the same samplea
Outcome
Unadjusted model 1st adjusted modelb 2nd adjusted modelc
IRR/Coeff 95% CI P IRR/Coeff 95% CI P IRR/Coeff 95% CI P
PCRconcn
HRV, no symptoms 1.12 0.88 to 1.41 0.35 1.17 0.92 to 1.48 0.2 1.14 0.90 to 1.44 0.27
HRV, symptoms 1.44 1.19 to 1.76 0 1.38 1.13 to 1.68 0 1.3 1.06 to 1.58 0.01
SDI
HRV, no symptoms 0.05 0.06 to 0.17 0.371 0.02 0.09 to 0.14 0.689 0.03 0.09 to 0.14 0.677
HRV, symptoms 0.18 0.28 to 0.07 0.001 0.18 0.29 to 0.08 0.001 0.17 0.28 to 0.07 0.001
Corynebacteriaceae
HRV, no symptoms 1.31 0.91 to 1.88 0.142 1.22 0.85 to 1.74 0.28 1.28 0.90 to 1.83 0.174
HRV, symptoms 0.91 0.64 to 1.30 0.611 1.04 0.73 to 1.48 0.828 1.1 0.78 to 1.55 0.588
Moraxellaceae
HRV, no symptoms 0.81 0.58 to 1.12 0.208 0.91 0.65 to 1.27 0.584 0.89 0.64 to 1.24 0.49
HRV, symptoms 1.22 0.93 to 1.59 0.154 1.3 0.98 to 1.71 0.067 1.22 0.92 to 1.60 0.164
Pasteurellaceae
HRV, no symptoms 0.85 0.55 to 1.32 0.476 0.94 0.60 to 1.48 0.801 0.97 0.61 to 1.53 0.895
HRV, symptoms 0.88 0.61 to 1.28 0.511 0.85 0.58 to 1.24 0.386 0.86 0.59 to 1.25 0.427
Staphylococcaceae
HRV, no symptoms 1.37 0.94 to 2.01 0.103 1.2 0.82 to 1.76 0.348 1.24 0.84 to 1.83 0.282
HRV, symptoms 0.67 0.46 to 1.00 0.049 0.72 0.49 to 1.07 0.108 0.78 0.52 to 1.17 0.23
Streptococcaceae
HRV, no symptoms 0.9 0.67 to 1.22 0.503 0.89 0.66 to 1.22 0.478 0.92 0.67 to 1.25 0.582
HRV, symptoms 0.8 0.61 to 1.05 0.111 0.81 0.62 to 1.07 0.135 0.86 0.65 to 1.13 0.272
Carnobacteriaceae
HRV, no symptoms 1.21 0.80 to 1.85 0.37 1.14 0.74 to 1.77 0.543 1.15 0.75 to 1.78 0.522
HRV, symptoms 0.74 0.50 to 1.11 0.142 0.69 0.45 to 1.03 0.071 0.72 0.48 to 1.09 0.118
Others
HRV, no symptoms 0.85 0.64 to 1.13 0.259 0.81 0.61 to 1.08 0.147 0.82 0.62 to 1.09 0.174
HRV, symptoms 0.7 0.54 to 0.90 0.006 0.66 0.51 to 0.85 0.001 0.7 0.54 to 0.90 0.006
aAnalyses of the microbiota of samples with symptomatic and asymptomatic HRV colonization. Baseline samples are free of virus. Baseline (no virus in sample), n 
318; asymptomatic HRV infection, n  51; symptomatic HRV infection, n  69. Coinfections are not included.
bAdjusted for age and season.
cAdjusted for age, season, siblings, child care, breastfeeding, hypoallergenic nutrition, C-section, smoking in pregnancy, maternal atopy, parental education.
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Findings were conﬁrmed when samples with viral coinfections in the swab were
included (results not shown) or in analyses adjusted for age and season and other risk
factors (ﬁrst and second groups of “Adjusted model” columns in Table 3, respectively).
Results were veriﬁed in two sensitivity analyses: (i) excluding samples with a lower
number of reads and (ii) if rareﬁed to 500 reads per sample (see Tables S2 and S3 in the
supplemental material). To reassure that possible changes in the microbiota were due
to viral colonization and were not the result of respiratory symptoms per se, we
performed additional analyses, including samples free of virus with and without
respiratory symptoms separately in the model (see Table S4 in the supplemental
material). Results were not different from the calculations presented above, where
samples free of virus irrespective of symptoms were used as the baseline. For further
analysis, to obtain better statistical power, we thus referred to samples free of virus with
and without respiratory symptoms as the baseline for comparison when investigating
the microbiota during colonization of the different viruses.
The presence of “viruses other than HRV” was not associated with changes in
bacterial density (PCRconcn), alpha diversity (SDI), or beta diversity (Jaccard dissim-
ilarity) of the microbiota or any differences in the abundance of the bacterial
families (see Table S5 in the supplemental material). We did not analyze associa-
tions of the different viruses separately, because occurrence was too rare for useful
statistical analysis.
Changes in the microbiota after viral colonization. To investigate persistence
of changes, we analyzed changes of the microbiota within 3 weeks after viral detection,
as depicted in analysis II in Fig. 1. Because only symptomatic HRV colonization had
shown an effect in analysis I, in this next step, we included in our analysis only cases of
symptomatic HRV colonization and compared them to samples free of virus. Again we
received signiﬁcant differences in alpha diversity (SDI, 1.0 [SD, 0.7] versus 1.4 [SD, 0.9]),
but the effect size was not as large (Table 4). Beta diversity, calculated by using nMDS,
did not reach statistical signiﬁcance, but trends were consistent (Jaccard, P  0.1;
Bray-Curtis, P  0.12) (see Fig. S3A in the supplemental material). On the bacterial
family level, the lower abundance of “others” remained (22% [24%] versus 33% [34%]),
in addition we found a signiﬁcantly higher abundance of Moraxellaceae (41.0% [36%]
versus 28% [37%]) and a lower abundance of Staphylococcaceae (0.4% [0.8%] versus
5.4% [18.9%] after symptomatic HRV infections. For detailed results see Table 4. Results
were conﬁrmed in the two sensitivity analyses (results not shown).
Although changes in the microbiota during symptomatic HRV infections were highly
signiﬁcant if pooled (Fig. 3A), individual courses showed a heterogeneous picture
FIG 2 Beta diversity of the microbiota during HRV colonization. Shown is a comparison of the
bacterial composition in samples without viral colonization to that in samples with asymptomatic
and symptomatic HRV colonization. Weighted beta diversities are represented by using nonmetric
multidimensional scaling (NMDS). Arrows indicate clustering of samples without viral colonization
(no.virus), HRV colonization without symptoms (HRV.no.symp), and HRV infection with symptoms
(HRV.symp). There is a significant difference in beta diversity during symptomatic HRV colonization
(“Adonis” function of R; P  0.04).
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(Fig. 3B), indicating large interindividual differences and suggesting that a personalized
microbiota in each individual exists.
Microbiota as a factor inﬂuencing subsequent HRV colonization. To assess
whether microbiota inﬂuences the occurrence and/or severity of subsequent viral
infections, as shown in analysis III in Fig. 1, we investigated the association of preex-
isting microbial composition on viral colonization within the following 3 weeks. Neither
alpha diversity nor beta diversity (Fig. S3B), bacterial density, nor the abundances of the
bacterial families were associated with a higher prevalence of HRV colonization at the
following swab. Furthermore, we found that none of the analyzed microbiota outcome
parameters had an inﬂuence on whether or not subsequent HRV colonization was
accompanied by respiratory symptoms (see Table S6 in the supplemental material).
Persistent changes of the microbiota after frequent HRV colonization. To
assess long-term consequences, we evaluated the overall inﬂuence of frequent HRV
colonization on the microbiota of the last 3 months of the study. The mean number of
samples per child was 6 (range, 4 to 8) in 31 infants, as one infant stopped the study
at 8 months of age.
More frequent symptomatic HRV infections during the ﬁrst year of life were asso-
ciated with a lower SDI at the end of the study period (SDI coeff, 0.5; 95% CI, 1.0 to
0.01; P  0.042) (Fig. 4A). This was not found in infants with more frequent asymp-
tomatic HRV colonization (SDI coeff, 0.2; 95% CI, 0.7 to 0.3; P  0.4) or more
frequent symptomatic infections of “viruses other than HRV” (SDI coeff, 0.04; 95% CI,
0.6 to 0.7; P  0.9) (Fig. 4B and C). Changes were not due to differences of SDI at
baseline, as baseline SDI values were comparable between different groups at the age
TABLE 4 Unadjusted and adjusted analysis of the association of symptomatic HRV colonization with the microbiota within 3 weeks after
HRV colonizationa
Outcome
Unadjusted model 1st adjusted modelb 2nd adjusted modelc
IRR/Coeff 95% CI P IRR/Coeff 95% CI P IRR/Coeff 95% CI P
PCRconcn 1.4 1.10 to 1.78 0.007 1.3 1.02 to 1.67 0.035 1.24 0.97 to 1.58 0.092
SDI 0.1 0.23 to 0.03 0.124 0.14 0.27 to 0.01 0.035 0.13 0.26 to 0.00 0.05
Corynebacteriaceae 1.02 0.67 to 1.54 0.942 1.04 0.68 to 1.58 0.86 1 0.66 to 1.51 0.996
Moraxellaceae 1.68 1.21 to 2.32 0.002 1.74 1.23 to 2.46 0.002 1.48 1.04 to 2.10 0.03
Pasteurellaceae 0.94 0.59 to 1.51 0.807 0.85 0.53 to 1.38 0.521 0.84 0.52 to 1.36 0.483
Staphylococcaceae 0.57 0.35 to 0.94 0.028 0.54 0.32 to 0.92 0.022 0.54 0.32 to 0.93 0.026
Streptococcaceae 0.98 0.71 to 1.37 0.927 0.91 0.65 to 1.27 0.573 0.93 0.66 to 1.30 0.656
Carnobacteriaceae 0.86 0.54 to 1.37 0.527 0.82 0.51 to 1.32 0.414 0.84 0.52 to 1.35 0.472
Others 0.71 0.52 to 0.98 0.039 0.69 0.49 to 0.95 0.026 0.71 0.51 to 0.99 0.044
aAnalysis of the microbiota 3 weeks after symptomatic HRV colonization, if then free of symptomatic HRV compared to samples that had no virus 3 weeks before.
Baseline (no virus in sample), n  256; symptomatic HRV infection, n  42. Coinfections are not included.
bAdjusted for age and season.
cAdjusted for age, season, siblings, child care, breastfeeding, hypoallergenic nutrition, C-section, smoking in pregnancy, maternal atopy, and parental education.
FIG 3 SDI values before, during, and after symptomatic HRV colonization. (A) Mean (95% CI) of SDI
before, during, and after symptomatic HRV colonization. All samples are included. (B) Individual
values of SDI before, during, and after symptomatic HRV colonization. Presented are only swabs with
the following characteristics: three consecutive samples with the one before HRV colonization free of
any viral colonization, the sample during HRV colonization without coinfection, and the sample after
HRV colonization free of any viral colonization.
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of 3 months or younger (data not shown). Findings were robust if coinfections were
included and showed a linear association (see Fig. S4 in the supplemental material).
DISCUSSION
Our study is the ﬁrst longitudinal study describing the interaction of viral colonization
with the upper respiratory tract microbiota in the ﬁrst year of life using such a dense
sampling frequency. The weekly monitoring of respiratory symptoms enabled us to
distinguish between symptomatic and asymptomatic episodes of viral colonization.
Analyzing 559 biweekly nasal samples, we found a strong and robust association
between HRV colonization and changes in the microbiota. During symptomatic HRV
colonization, a lower alpha diversity (SDI), a higher bacterial density (PCRconcn), and a
difference in beta diversity (Jaccard and Bray-Curtis dissimilarities) of the microbiota
were found. In contrast, during asymptomatic HRV colonization, no changes in the
microbiota were detected. Results remained stable if distinguishing between symp-
tomatic and asymptomatic samples free of virus, indicating that changes in the
microbiota are not driven by symptoms per se but by HRV infection. Furthermore, in
addition to the short-term changes, more frequent symptomatic HRV infections had a
sustained impact upon the composition of the microbiota.
To our knowledge, an investigation of viral colonization of the nose and the nasal
microbiota in infancy has only been published once (23). In that Australian study,
sampling was performed two or three times in each infant, so persisting changes were
not investigated. The authors concluded that viruses and the microbiota contribute
independently to the later onset of asthma, but the underlying interactions between
virus and bacteria were not assessed on a short-term basis. Apart from that study, the
impact of symptomatic HRV infection on bacterial colonization has been reported only
in older children (24). The authors reported a higher detection rate and a higher
quantity of bacteria during HRV infection in children of ages 4 to 12 years, as well as an
association of speciﬁc bacteria and HRV infection with asthma symptoms.
As reported before from adult studies, we found a lower diversity and a higher
density during symptomatic HRV colonization (20, 25, 26). The rather high intra- and
interindividual heterogeneity is also in line with previous data (10, 25) and supports the
hypothesis of a different composition of the microbiota during viral infection (27),
possibly explained by an outgrowth of potential pathogens triggered through HRV.
One drawback of existing studies investigating the microbiota and viral infections is
the lack of including samples during asymptomatic periods of viral colonization, as
information about asymptomatic HRV colonization in infancy is scarce in general (13,
28, 29). This is, however, needed if one aims to differentiate between asymptomatic
FIG 4 SDI at the end of the first year of life in relation to the number of viral colonizations throughout the whole year. Shown are the median SDIs of
the nasal swabs taken in the last 3 months of the study period (box plots with minimum to maximum) grouped as from zero to two positive swabs and
as more than two positive swabs for (A) symptomatic HRV (0 to 2, n  18; >2, n  13), (B) asymptomatic HRV (0 to 2, n  20; >2, n  11), and (C)
symptomatic viral infections other than HRV (0 to 2, n  21; >2, n  10). Coinfections are only included for symptomatic viral infections other than HRV.
A lower SDI was found in infants with more frequent symptomatic HRV colonization (P  0.015) but not with more frequent asymptomatic HRV
colonization (P  0.2) or more frequent symptomatic viral colonization other than HRV (P  0.1).
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HRV colonization and HRV infection. In our study, only symptomatic HRV infections
were associated with changes in the microbiota. Importantly, we could also show that
respiratory symptoms alone did not have the effect on the composition of the micro-
biota, indicating that a certain immune response of the individual subject driven by
viruses is needed to result in changes of the microbiota (30).
The changes in the microbiota did partly persist 3 weeks after viral colonization,
although the association was less strong. Studies in adults reported no sustained
changes in healthy subjects (20), whereas in chronic obstructive pulmonary disease
(COPD) patients, a higher abundance of Haemophilus inﬂuenzae and an increase in 16S
rRNA gene copy number could be seen up to 42 days after infection (20). Our ﬁnding
of a higher abundance of Moraxellaceae and a lower abundance of Staphylococcaceae
after HRV infection was not reported before, but other studies described an association
of a higher abundance ofMoraxellaceae with acute respiratory infections (ARIs) (23) and
viral colonization (26). These results support the hypothesis of persistent bacterial
outgrowth after viral infection, especially as Moraxella catarrhalis is a potential patho-
gen in respiratory disease (1).
Similar to previous data from adults, in our study, the microbiota composition was
no risk factor for subsequent viral colonization and had no impact upon occurrence or
severity of HRV infections (25). This suggests an inﬂuence of the virus on the microbiota
and not vice versa; however, to clearly examine this, “virus-naïve” samples should be
assessed in future studies.
The lower SDI at the end of the study period in infants with more frequent
symptomatic HRV further suggests continuing changes in the microbiota and is in line
with recent results (23), representing a speculative but possible link to later disease
development. It is yet unclear if it is the frequency of infections, the time period during
which they occur, or preexisting susceptibility that is most important for persisting
changes in the microbiota. In addition, although the difference in alpha diversity was
highly signiﬁcant, rather high inter- and intraindividual standard deviations have to be
kept in mind before considering it as potential clinical marker. However, if conﬁrmed in
other studies, alpha diversity could be used as an easy outcome parameter to assess
individual susceptibility toward ongoing microbial alterations upon viral infections and
potentially later disease development.
A major strength of our study is the dense sampling within the ﬁrst year of life.
Furthermore, data assessment was not restricted to periods of illness or scheduled
visits. Our study provides longitudinal data on the dynamic interplay between virus and
the microbiota in the ﬁrst year of life, considering 12 different viruses. Due to rare
occurrence, we could not obtain clear results for all viruses; however, with the high
number of different viruses analyzed, we can differentiate between samples free of
virus, those free of viral coinfection, and those with viral infection; the weekly infor-
mation and longitudinal sampling further allowed us to assess associations in both
directions with different time lags. Having detailed information of pre-, peri-, and
postnatal history and exact documentation of any changes of sociodemographic and
environmental factors, including family history for atopy, we were able to adjust for
several known confounders and other risk factors, ensuring results are robust.
A limitation is the small number of study infants. Despite the high number of
samples, a larger study population is needed to detect additional differences between
subjects. Importantly, analysis of viruses and the microbiota during respiratory infec-
tions in a higher number of infants is needed to understand the role of viruses other
than HRV. Also, the causal and mechanistic pathways between symptomatic HRV
infections and the microbiota remain unclear: these need to be assessed in translational
approaches or using animal models.
Viral and bacterial colonization are thought to be causal in acute respiratory
morbidity, as well as in the later development of chronic diseases, such as asthma or CF
(7, 14, 20). Especially HRV infections drive speciﬁc and nonspeciﬁc immune reactions
and inﬂammation (31) through dendritic cells, macrophages, and epithelial cells and a
number of cytokines (32–34). If future studies including sampling of local or systemic
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inﬂammatory processes (35, 36) can show that those mechanisms play an important
role in viral colonization during infancy and in shaping the microbiota-immune balance,
preventative measures, such as vaccination or application of probiotics, could be
directed against those processes. Although further studies are clearly needed to
conﬁrm this hypothesis, the ﬁrst studies have already shown a possibly preventive
effect of probiotics on respiratory infection in general and HRV infection in particular
(37, 38).
We conclude that symptomatic HRV infections are associated with a short-term
change in bacterial density and diversity of the microbiota and that more frequent
symptomatic HRV infections have a long-term impact upon the diversity of the micro-
biota at the end of the ﬁrst year of life. This indicates a dynamic interaction between
HRV infections and the respiratory microbiota in early life. Although the long-term
importance of these interactions needs to be examined in future follow-up studies, our
ﬁndings could be of signiﬁcance for preventive or therapeutic procedures.
MATERIALS AND METHODS
Study design and subjects. Thirty-two healthy, unselected infants from the ongoing prospective
Basel-Bern Infant Lung Development (BILD) cohort study were included between April 2010 and February
2013 (39). Pregnant mothers were recruited at maternity hospitals and practices of obstetricians by
advertisements and interviews. Exclusion criteria for the BILD cohort study and thus our subgroup
analysis are ethnicity other than white, preterm delivery (37 weeks), major birth defects, disease or later
diagnosis of airway malformation, or speciﬁc chronic respiratory disease.
A weekly telephone interview was performed by study nurses to assess respiratory health. This
substudy was performed in Bern only and thus approved by the Ethics Committee Bern.
Nasal swab procedure. An anterior nasal swab (FLOQSwabs, in room temperature universal trans-
port medium [UTM-RT]; Copan, Italia) was collected biweekly by parents after being instructed by study
nurses about correct and standardized sampling of the swabs, starting in the ﬁfth week of life.
Immediately after acquisition, nasal swabs were sent to our study center and frozen at 80°C. The
microbiota, 10 different viruses, and two atypical bacteria were analyzed in each sample.
Microbiota analysis. The methods used for PCR ampliﬁcation of the 16S ribosomal RNA (rRNA)
gene and 454 amplicon sequencing are described in detail elsewhere (10, 40). In brief, V3 to V5
regions of the bacterial 16S rRNA genes were ampliﬁed using the primer pair 341F/907R. The following
primers were used: 341F (5=-CGTATCGCCTCCCTCGCGCCATCAGXXXXXXXXXXACTCCTACGGGAGGCAG
CAG-3=) and 907R (5=-CTATGCGCCTTGCCAGCCCGCTCAGXXXXXXXXXXCCGTCAATTCMTTTGAGTTT-3=).
The template-speciﬁc sequences are in boldface, adaptor sequences are italicized, and the XXXXXXXXXX
sequences describe the sample-speciﬁc multiplex identiﬁer (MID) tag barcode. PCR mixtures were eluted
in 40 l of double-distilled water, after puriﬁcation with the Wizard SV PCR cleanup system (Promega,
Madison, WI). PCR products with a concentration of less than 1.0 ng/l were excluded from the study,
corresponding to less than 1 pg/l bacterial DNA (10), which was recently recommended as a reliable
threshold (41). For further quality control, we excluded samples with less than 70 reads and sequenced
two negative-control samples. Samples displaying greater than 5% sequence reads identical to the
negative controls were excluded. In addition, we did not identify taxa that have recently been identiﬁed
to be contaminations (42). A 40-ng/l concentration of each PCR product was pooled, and every MID was
used once. The 8 resulting amplicon pools were sequenced with the 454 sequencing platform, and the
reads were submitted to the National Center for Biotechnology Information Sequence Read Archive.
Analysis of sequencing products was performed using PyroTagger pipeline (43), which comprises the
deﬁnition of operational taxonomic units (OTUs) based on 97% sequencing identity, estimation of
chimeras, and taxonomic assignments. Pipeline settings were described in detail before (40). As an
additional quality cutoff, samples with less than 70 sequence reads were excluded from the study (n 
13), resulting in a minimum number of reads of 77. The mean number of sequence reads was, however,
much higher (1,469 [SD, 1,083] reads per sample).
Outcome parameters were bacterial density estimated by the concentration of the 16S rRNA PCR
product (PCRconcn) in nanograms per microliter, alpha diversity assessed by the Shannon diversity index
(SDI, based on OTUs of 97% sequence identity), and beta diversity, the latter both calculated in R using
the “vegan” package. For beta diversity, dissimilarity indices were calculated using the Jaccard distance
method and the Bray-Curtis dissimilarity, and nMDS was used as the ordination method. Again, beta
diversity measurements were based on OTUs of 97% sequence identity.
The ﬁve most abundant bacterial families (Streptococcaceae, Staphylococcaceae, Moraxellaceae, Co-
rynebacteriaceae, and Pasteurellaceae) and Carnobacteriaceae (which were formerly described in interre-
lationship with respiratory infections [23]) were analyzed, and the remaining families were grouped as
“others.” This phylogenetic level was used for additional statistical analyses (see below).
Virological analysis. The following different viruses and atypical bacteria were used as outcome
parameters in our analysis: inﬂuenza A and inﬂuenza B viruses, RSV, human metapneumovirus (hMPV),
adenovirus (ADV), human Bocavirus (hBoV), rhinovirus/enterovirus (HRV/EV), parechovirus, coronavirus
(HCoV), parainﬂuenzavirus (HPIV), and Mycoplasma pneumoniae and Chlamydia pneumoniae.
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The samples were tested by real-time PCR, using a combination from the 7-duplex Respiratory
multiwell system (MWS) r-gene (inﬂuenza virus A/B, RSV/hMPV, rhinovirus and EV/cellular gene control
[CC], ADV/hBoV, HCoV/HPIV, C. pneumoniae/M. pneumoniae, and parechovirus) commercialized by
Argene/BioMérieux (Marcy l’Etoile, France), according to the manufacturer’s instructions. RNA and DNA
were extracted from a 400-l sample with the NucliSENS easyMAG (bioMérieux, Marcy l’Etoile, France)
according to the manufacturer’s instructions and eluted in 110 l.
The real-time PCR was performed on different real-time PCR machines of Applied Biosystems (7500,
7900HT; QuantStudio 7 Flex).
The hypoxanthine phosphoribosyltransferase 1 (HPRT1) cellular gene control (CC) essay using the
duplex rhinovirus and EV/CC r-gene samples was used to evaluate sampling quality, extraction, and
ampliﬁcation in every sample. Samples showing an exponential ampliﬁcation curve with a threshold
cycle (CT) value of 45 were assessed as positive.
The PCR tests were done by a certiﬁed laboratory that has routinely used the CE-marked Respiratory
MWS r-gene for the detection of respiratory viruses since 2012.
For easier reading, the term “viral analysis” is used in the text, although two atypical bacteria are also
included in the analysis.
Respiratory symptoms. In weekly standardized telephone interviews, symptoms of lower and upper
respiratory tract infections, wheeze, and/or cough were recorded. Rhinitis (runny or blocked nose) was
independently assessed as the most common upper respiratory symptom. For data analysis, if referring
to symptomatic viral infection, we combined upper and lower respiratory symptoms. If referring to URTI,
cough and/or wheeze had to be present. An LRTI was deﬁned as cough, wheeze, or breathing difﬁculties
and upper respiratory tract symptoms or elevated temperature for more than 2 consecutive days. A viral
infection was speciﬁed as symptomatic if any respiratory symptoms occurred up to 4 days before until
7 days after detection of viral colonization in the sample.
Additional risk factors or confounders. Information about pre-, peri-, and postnatal history,
including family, maternal, sociodemographic, and environmental histories, was collected in hospital
records and with a questionnaire. At the time of the weekly standardized phone interview, changes in
host and environmental factors were documented. The following factors were included in our statistical
model to adjust for potential confounders: the time-invariant factors included in our study were maternal
atopic disease (maternal asthma, hay fever, or eczema), parental education (categorized as low [less than
4 years of secondary education], middle [at least 4 years of secondary education], and high [tertiary
education]), mode of delivery (C-section or vaginal delivery), smoking during pregnancy, and presence
of older siblings. The time-variant factors included were age and season of sampling, breastfeeding
(“current” [yes/no] at time of swab), hypoallergenic nutrition (“current” [yes/no] at time of swab), and
child care (“current” [yes/no] at time of swab).
Statistical analysis. We investigated the association between viral colonization and the microbiota
using multilevel regression with random effect to correct for clustering on the individual level. We
performed binomial multilevel regression to analyze bacterial families and PCRconcn. In a subgroup
analysis, zero inﬂated binomial regression was not a better statistical model than regular binomial
regression (Vuong test for model selection) and thus was not used. Diversity (SDI) was analyzed with
multilevel linear regression after transformation (square root [sqrt]) to obtain a normal distribution.
We investigated an association between viral colonization and the microbiota in the same sample
(Fig. 1; analysis I), the microbiota after viral colonization (Fig. 1; analysis II), and the microbiota before viral
colonization (Fig. 1; analysis III).
After performing a univariable model (no adjustment), two adjusted models were performed. In
the ﬁrst adjusted model, an adjustment for season and age was performed, because both inﬂuence
the microbiota (10). In the second adjusted model, we adjusted for further risk factors of respiratory
symptoms or viral infections in early life: having siblings, mode of delivery, child care, hypoallergenic
nutrition, breastfeeding, parental education, smoking during pregnancy, and maternal atopy (44–
48). To analyze the microbiota at the end of the study period, we calculated the median of the
different microbiota outcome parameters of all existing samples of an infant between 9 and
12 months of age.
We used two different indices to calculate the diversity between samples. The Bray-Curtis
dissimilarity and the Manhattan-type Jaccard dissimilarity were used to calculate the weighted beta
diversity indices (abundance based), by using the “vegdist” function of the “vegan” package in R. For
nMDS, “metaMDS” of the vegan package was used. To analyze differences in beta diversity, the
“Adonis function” was used as a permutational multivariate analysis of variance (PERMANOVA)
analysis, and adjustment for multiple measurements was applied (“strata” operator in the Adonis
function).
We performed two sensitivity analyses to ensure robustness of results. We excluded the samples with
a number of reads below 500 (n  84) and (i) repeated the main analyses as stated above. With this
approach the range of number of sequences per sample between the different samples is much smaller.
(ii) The total number of sample reads was randomly resampled to an equal number of reads and rareﬁed
to 500, using the “rrarefy” command of the vegan package in R. Subsample analysis in all remaining
samples with 500 reads (n  475) was performed.
Results are represented as coefﬁcients (Coeff), incidence rate ratios (IRR), or odds ratios (OR) with 95%
conﬁdence intervals (CIs) and P values; P values of 0.05 were considered statistically signiﬁcant. All
analyses were done using Stata13 (College Station, TX), R (“vegan package” “Adonis function”) version
3.1.1 (R Foundation of Statistical Computing), and GraphPad Prism 5.
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Accession number(s). Reads of this study are part of the sequencing data deposited in NCBI’s
Sequence Read Archive under GenBank accession no. SRP041616.
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